Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm
- PMID: 33104881
- PMCID: PMC7782416
- DOI: 10.1007/s00277-020-04304-y
Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm
Abstract
Bone marrow (BM) fibrosis in myeloproliferative neoplasms (MPNs) is associated with a poor prognosis. The development of myelofibrosis and differentiation of mesenchymal stromal cells to profibrotic myofibroblasts depends on macrophages. Here, we compared macrophage frequencies in BM biopsies of MPN patients and controls (patients with non-neoplastic processes), including primary myelofibrosis (PMF, n = 18), essential thrombocythemia (ET, n = 14), polycythemia vera (PV, n = 12), and Philadelphia chromosome-positive chronic myeloid leukemia (CML, n = 9). In PMF, CD68-positive macrophages were greatly increased compared to CML (p = 0.017) and control BM (p < 0.001). Similar findings were observed by CD163 staining (PMF vs. CML: p = 0.017; PMF vs. control: p < 0.001). Moreover, CD68-positive macrophages were increased in PV compared with ET (p = 0.009) and reactive cases (p < 0.001). PMF had higher frequencies of macrophages than PV (CD68: p < 0.001; CD163: p < 0.001) and ET (CD68: p < 0.001; CD163: p < 0.001). CD163 and CD68 were often co-expressed in macrophages with stellate morphology in Philadelphia chromosome-negative MPN, resulting in a sponge-like reticular network that may be a key regulator of unbalanced hematopoiesis in the BM space and may explain differences in cellularity and clinical course.
Keywords: Bone marrow fibrosis; Immunohistochemistry; Macrophages; Myeloproliferative neoplasm.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures





Similar articles
-
Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.Ann Hematol. 2021 Jan;100(1):105-116. doi: 10.1007/s00277-020-04306-w. Epub 2020 Oct 21. Ann Hematol. 2021. PMID: 33089365
-
GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms.Leuk Res. 2021 Jan;100:106495. doi: 10.1016/j.leukres.2020.106495. Epub 2020 Dec 15. Leuk Res. 2021. PMID: 33360878
-
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations.Br J Haematol. 2008 Jan;140(2):162-8. doi: 10.1111/j.1365-2141.2007.06885.x. Epub 2007 Nov 19. Br J Haematol. 2008. PMID: 18028479
-
Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).Int J Hematol. 2002 Aug;76(2):133-45. doi: 10.1007/BF02982575. Int J Hematol. 2002. PMID: 12215011 Review.
-
Diagnostic criteria of the myeloproliferative disorders (MPD): essential thrombocythaemia, polycythaemia vera and chronic megakaryocytic granulocytic metaplasia.Neth J Med. 1997 Aug;51(2):57-64. doi: 10.1016/s0300-2977(97)00018-1. Neth J Med. 1997. PMID: 9286142 Review.
Cited by
-
JAK2 Variant Signaling: Genetic, Hematologic and Immune Implication in Chronic Myeloproliferative Neoplasms.Biomolecules. 2022 Feb 11;12(2):291. doi: 10.3390/biom12020291. Biomolecules. 2022. PMID: 35204792 Free PMC article. Review.
-
Potential application of the bulk RNA sequencing in routine MPN clinics.BMC Cancer. 2025 Apr 22;25(1):746. doi: 10.1186/s12885-025-13947-x. BMC Cancer. 2025. PMID: 40264064 Free PMC article.
-
Megakaryocytes Are Regulators of the Tumor Microenvironment and Malignant Hematopoietic Progenitor Cells in Myelofibrosis.Front Oncol. 2022 May 11;12:906698. doi: 10.3389/fonc.2022.906698. eCollection 2022. Front Oncol. 2022. PMID: 35646681 Free PMC article. Review.
-
Circulating Monocytes Contribute to Erythrocyte Clearance in Polycythemia Vera.Int J Mol Sci. 2025 May 27;26(11):5133. doi: 10.3390/ijms26115133. Int J Mol Sci. 2025. PMID: 40507944 Free PMC article.
-
Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC-Alarmin Axis.Blood Cancer Discov. 2024 Jul 1;5(4):276-297. doi: 10.1158/2643-3230.BCD-23-0210. Blood Cancer Discov. 2024. PMID: 38713018 Free PMC article.
References
-
- Romano M, Sollazzo D, Trabanelli S, Barone M, Polverelli N, Perricone M, Forte D, Luatti S, Cavo M, Vianelli N, Jandus C, Palandri F, Catani L. Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis. Oncoimmunology. 2017;6:e1345402. doi: 10.1080/2162402X.2017.1345402. - DOI - PMC - PubMed
-
- Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martínez-Trillos A, Casetti I, Colomer D, Pieri L, Pratcorona M, Rotunno G, Sant'Antonio E, Bellini M, Cavalloni C, Mannarelli C, Milanesi C, Boveri E, Ferretti V, Astori C, Rosti V, Cervantes F, Barosi G, Vannucchi AM, Cazzola M, Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124:1062–1069. doi: 10.1182/blood-2014-05-578435. - DOI - PMC - PubMed
MeSH terms
Grants and funding
- SFB/TRR57, SFB/TRR219, BO3755/3-1, BO3755/6-1/Deutsche Forschungsgemeinschaft
- KO2155/7-1/Deutsche Forschungsgemeinschaft
- SCHN1188/6-1/Deutsche Forschungsgemeinschaft
- STOP-FSGS-01GM1901A/Bundesministerium für Bildung und Forschung
- O3-2/Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg (DE)
LinkOut - more resources
Full Text Sources
Research Materials